The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 10, 2026

Filed:

Jun. 01, 2020
Applicants:

Vogenx, Durham, NC (US);

Kissei Pharmaceutical Co., Ltd., Azumino, JP;

Inventors:

Wiliam Owen Wilkison, Raleigh, NC (US);

Bentley Cheatham, Durham, NC (US);

James Trinca Green, Raleigh, NC (US);

Yoshikazu Fujimori, Azumino, JP;

Assignee:

VOGENX, Durham, NC (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/706 (2006.01); A61K 31/7012 (2006.01); A61K 31/7056 (2006.01); A61P 3/10 (2006.01); A61K 9/00 (2006.01);
U.S. Cl.
CPC ...
A61K 31/706 (2013.01); A61K 31/7012 (2013.01); A61K 31/7056 (2013.01); A61P 3/10 (2018.01); A61K 9/0053 (2013.01);
Abstract

The invention described herein relates to oral dosage form therapies for treating metabolic disorders using combinations of inhibitors of SGLT1 and SGLT2. In such dosage forms, SGLT1 is effective in the intestinal lumen, and is either not absorbed, or poorly absorbed, while the SGLT2 inhibitor inhibits sugar reabsorption in the kidney by inhibiting SGLT2 activity. Metabolic disorders treated by combined SGLT1 and SGLT2 oral dosage forms include disorders associated with abnormal accumulation of liver lipids, which may also be copresent with hyperglycemia. Combinations of SGLT1 and SGLT2 inhibitors are contemplated herein, particularly combinations.


Find Patent Forward Citations

Loading…